Researchers in Oregon looked for discrepancies between published and unpublished FDA-registered trials. They found that four of the 24 FDA-registered trials of second-generation antipsychotics identified were unpublished. The mean effect size of the published trials was approximately double that of the unpublished trials. Results appeared this week in PLoS Medicine.
Article →
Related articles:
Washington Post
Medscape
Sydney Morning Herald
Fox News
Psych Central
ABC News
